Someit Sidhu

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Lanark Master Issuer Plc is a special purpose company, which engages in issuing asset-backed securities. Its principal objectives are to lend money and give credit, secured and unsecured; to borrow and raise money; and to grant security over its property for the performance of its obligations and the payment of money. The company was founded on July 5, 2007 and is headquartered in London, the United Kingdom.

Part of Deutsche Bank AG, Heta Funding Designated Activity Co. is an Irish investment advice company. The company is based in Dublin, Ireland. Founded in 2009.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia.

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

SMART Reading offers literacy support to children. It helps kids become confident readers by providing individual volunteer attention and new, take-home books. The company was founded in 1992 and is headquartered in Portland, OR.

Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ.

Part of BL Sainsbury Superstores Ltd., Blssp PHC 27 Ltd. provides property investment services. The company is based in London, UK.

Part of BL Sainsbury Superstores Ltd., BLSSP (PHC 30) Ltd. provides property investment services. The company is based in London, UK and was founded in 2000.

Part of Virgin Money UK Plc, Lanark Funding Ltd. is a company that provides financial intermediary services. The company is based in London, UK.

InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.

Part of Virgin Money UK Plc, Lanark Trustees Ltd. provides investment services. The company is based in London, UK.

EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom.

Part of Castlewood CS Holdings Ltd., P2PCL 1 PLC is a British financial intermediary company founded in 2014. The company provides financial intermediation services and is based in London, UK.

Orbit Discovery Ltd. develops technology for discovery process and drug development. The company was founded by Terry Rabbitts and Graham Ogg and is headquartered in Oxford, the United Kingdom.

LifeMine Therapeutics, Inc. develops drugs from fungi which aims to cure untreatable and significant chronic diseases. The company was founded by Gregory L. Verdine, WeiQing Zhou, Richard D. Klausner and Hingge Hsu and is headquartered in Cambridge, MA.

Athanor Capital LP (Athanor) is a hedge fund manager headquartered in New York City. The firm was founded by Parvinder S. Thiara in 2017 and is a subsidiary of Athanor Capital GP LLC. Athanor serves as the investment adviser, with discretionary trading authority over private pooled investment vehicles.

Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom.

New Skye (UK) Ltd. was founded in 2009 and functions as a financing subsidiary/special purpose entity. The private company is based in London, UK.

Part of Massachusetts Mutual Life Insurance Co., Sapphire Aviation Finance I (UK) Ltd. is a British company that leases aircraft. The company is based in London, UK. Sapphire Aviation Finance I (UK was founded in 2018.

Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

UBER, Inc. retails outdoor sports products. The company was founded on February 2, 2007 and is headquartered in Fountain Valley, CA.